Telyrx Holdings Inc. · TSX:TELY
Telyrx — Investor Presentation (May 2026)
24 slides from Telyrx's investor presentation, May 14, 2026
Slide 1: TelyRx: Healthcare Reimagined, Prescriptions on Demand
Investor Presentation | May 2026 TelyRx: Healthcare Reimagined Prescriptions on Demand
Slide 2: Important Disclosures & Forward-Looking Statements
DISCLAIMER Important Disclosures & Forward-Looking Statements This presentationis for informationalpurposesonly anddoes not constitute an offerto sell or a solicitationof an offerto buy any securitiesof FUTURE-ORIENTEDFINANCIALINFORMATION Finco orTelyRxin anyjurisdictionwhere itwouldbe unlawfulto ma
Slide 3: Non-IFRS Measures
DISCLAIMER NON-IFRSMEASURES Free Cash Flow This presentationuses certainnon-IFRS measuresto evaluatethe performanceof the Company. The term“EBITDA”andAdjustedEarnings BeforeInterest,Taxes, DepreciationandAmortization(“AdjustedEBITDA”) and Free Cash Flow (“FCF”) do not have any standardized Free Cash
Slide 4: The wait is over.
The wait is over. TelyRx delivers essential medication directly to you with no friction, no delays, and no excuses.
Slide 5: Better access for the majority of Americans
Better access for the majority of Americans Access to 450+ everyday medications, with less time, cost, and complexity.
Slide 6: From click to doorstep!
The average American waits days to access medication Scheduling delays Driving to the doctor’s office Waiting for fulfillment Driving home from the pharmacy Submitting insurance claims Waiting In-person visit Driving the prescription to the pharmacy From click to doorstep! Your desired medication ca
Slide 7: What used to take days, now takes moments.
What used to take days, Skip the waiting room now takes moments. Skip the pharmacy Skip insurance paperwork No appointments No memberships No insurance required $22 physician review fee Fast doorstep delivery Browse our formulary Request the prescription A licensed provider reviews On approval, your
Slide 8: Access to everyday medications from our digital pharmacy platform
Access to everyday medications from our rapidly scaling, digital pharmacy platform 8 Categories* 60+Conditions 450+ Generic & branded drugs Ivermectin Chronic Conditions 2% Zepbound 2% 7% Albuterol Digestion 2% Tadalafil Flu & Infection Weight-loss 2% Mounjaro Azithromycin Men's Health 2% 4% Ozempic
Slide 9: Our 100% cash pay model permits vertical integration
Our 100% cash pay model permits Most pharmacies are dependent vertical integration on insurance revenue Physician Prescription Logistics & TelyRx Access Dispensing Fulfillment PhysicianAccess PrescriptionDispensing Logistics& Fulfillment Patients are choosing Insurance revenue prohibits convenience
Slide 10: Cash-pay is a huge market opportunity
Cash-pay is a huge market opportunity $585B $98B Cash-pay segment has grown at Total insured covered prescription market Cash-pay market1 40% CAGR2 1. U.S. 2. CAGR (2019-2024), data from www.pharmaceuticalcommerce.com, www.hmpglobal.com, and www.jrreport.wordandbrown.com
Slide 11: The market has shifted. Permanently.
The market has shifted. Permanently. Behavior has Traditional Federal law creates changed pharmacies competitive hurdle are closing1 Alignment with Consumers are Brick & mortar Regulation creates defensible telehealth and digital increasingly seeking pharmacies are seeing moat for vertically-integra
Slide 12: Engineered for National Scale with Minimal Capital Spend
Engineered for National Scale with Minimal Capital Spend 250,000 2,600 Average prescriptions per day (Q1 ’26) 99% Two licensed pharmacies in Texas and Florida servicing ~97% of the U.S. population across 48 states & territories Our distribution facilities are near major airports Dallas, TX Clearwate
Slide 13: Rapidly Scaling Patient & Revenue Growth with Strong Retention Metrics
Rapidly Scaling Patient & Revenue Growth with Strong Retention Metrics Revenue by New & Recurring Customers (in US$ 000s) $19,394 $6,734 $14,188 $12,337 $4,273 $4,462 $12,660 $9,342 $9,915 $6,931 $4,078 $7,874 $4,685 $3,335 $2,884 $2,391 $5,264 $1,505 $3,596 $458 $1,712 $2,294 $349 $956 $1,172 Q1'24
Slide 14: Predictable Customer Revenues
Predictable Customer Revenues Customer Lifetime Revenue by Quarter (US$/Customer) $524 69,000 New Customers in Q1 2026 ↑45% $104 Compounded Quarterly Growth Rate for New Customers (Q1 2024 – Q1 2026) 1 1 2 2 33 44 5 5 6 6 7 7 8 98 Quarters Quarters Since Since First First Purchase Purchase Quarterly
Slide 15: Return on marketing spend
Return on marketing spend Revenue US$ Millions 3.0x Return on Marketing Spend1 2.8x 2.4x $19.4 2.7x $14.2 2.6x $12.3 4.6x 4.7x $9.3 $8.1 5.8x $6.9 $5.3 $4.7 5.0x $4.6 $3.6 5.0x $2.9 $1.5 $1.5 $1.0 $0.5 $0.1 $0.3 $0.5 Q1'24A Q2'24A Q3'24A Q4'24A Q1'25A Q2'25A Q3'25A Q4'25A Q1'26A Revenue Marketing Sp
Slide 16: The TelyRx Marketing Plans & Strategies
The TelyRx Marketing Plans & Strategies Our Brand Promise Improved Access Convenience Trust
Slide 17: Marketing Efficiency: Revenue Tracks to Traffic Growth
Marketing Efficiency: Revenue Tracks to Traffic Growth $19,394 Website sessions growing nearly 20x from 0.3M to 6.1M quarterly $14,314 (Q1‘24 to Q1‘26) Website Sessions (# 000s) New Customer Revenue (US$ 000s) $12,337 In-house marketing advantage: $9,342 Direct control over campaigns and faster $6,9
Slide 18: Growing rapidly with focus on profitability
Growing rapidly with focus on profitability Financials Q1 Q1 YE Dec. 31 2025 2024 (US$ in millions) 2026 2025 ▪ Revenue visibility through high customer retention rate Revenue $19.4 $6.9 $42.9 $9.5 ▪ Currently reinvesting gross margins into Y/Y Growth 180% -- 352% -- customer acquisition (4.3x LTR/C
Slide 19: Competitive Landscape
Competive Landscape D2C Telehealth + Integrated Pharmacy Pharmacy & Fulfillment Telehealth Broad Offering Lifestyle Focused Digital Couriers Mail Order TelyRx ✓ Cash pay focused • Cash pay focused, primarily • Requires customers to • Requires customers to • Provides consultation & ✓ Front end telehe
Slide 20: Deeply Experienced & Dynamic Team
Deeply Experienced & Dynamic Team Big 4 financial controls $3.3B+ in exits E-commerce & DTC expertise Digital-first DNA Healthcare regulatory depth Vanessa Slowey John Cascio Peter Lloyd Rafael Jose Adam Gardner, Chief Executive CPA Chief Revenue Chief Digital PharmD Brand & customer acquisition at
Slide 21: Everyone needs medication. TelyRx delivers
Everyone needs Unmatched True Vertical medication. Breadth: 450+ Medications Integration TelyRx delivers convenience. Access to Cash-pay Our Proprietary Simplicity & Physician Stark Law Network Competitive Moat Zero Insurance Frictionless, Complexity Predictable, Fast Delivery
Slide 22: Appendix
Appendix
Slide 23: Customer Unit Economics
Customer Unit Economics Average 1st Transaction1 New Customer Day Count to Second Purchase Avg. Revenue $104 Gross Profit 58 47% of new customers convert into repeat customers 59% Less: CAC (113) of repeat customers make a second Less: Variable Pharmacy & Shipping Labor Cost (5) purchase within 30 d
Slide 24: Risk Factors
DISCLAIMER Risk Factors There are a number of risk factors that could impact the Resulting Issuer’s or the Company’s ability to successfully execute its key strategies and may materially affect future events, performance or results. The risks and uncertainties described herein are not the only ones